Compare PLBY & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLBY | CRBU |
|---|---|---|
| Founded | 1953 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.4M | 138.3M |
| IPO Year | 2020 | 2021 |
| Metric | PLBY | CRBU |
|---|---|---|
| Price | $1.37 | $0.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $2.83 | ★ $5.75 |
| AVG Volume (30 Days) | 618.3K | ★ 5.2M |
| Earning Date | 11-05-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.50 | 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $120,928,000.00 | N/A |
| Revenue This Year | $6.60 | $145.34 |
| Revenue Next Year | $5.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.13 | N/A |
| 52 Week Low | $0.95 | $0.41 |
| 52 Week High | $2.75 | $2.49 |
| Indicator | PLBY | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 78.46 | 27.96 |
| Support Level | $1.11 | $0.44 |
| Resistance Level | $1.60 | $0.58 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 94.60 | 29.62 |
Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.